Market appeal
4DMedical managing director and founder Andreas Fouras said the contract demonstrates the appeal of the company’s combined structural and functional lung analysis technologies for the US market.
“We are thrilled to secure this commercial contract with IPOC and are encouraged by growing interest from pulmonologists in the US, particularly after our recent educational initiatives with the California Thoracic Society,” he said.
“This validates our technology’s value in the clinical setting and strengthens our position in the market as we work to improve diagnostic options for patients suffering from unexplained dyspnoea and other respiratory ailments.”
Lung analysis
4DMedical’s CT LVAS technology provides a detailed analysis of lung ventilation and airflow, assisting clinicians in diagnosing and assessing respiratory diseases more effectively than traditional methods.
The addition of LDAf allows physicians to quantify lung structure which, when used alongside lung function, can add significant value in identifying and managing obstructive lung diseases.
The IPOC contract follows the recent signing of a three-year commercial deal with UC San Diego (UCSD) Health for the provision of advanced lung imaging analysis.
UCSD Health is ranked among the top ten hospitals in the US for respiratory care and the agreement will enable its doctors to utilise 4DMedical’s portfolio of advanced lung imaging products as part of their clinical approach.
Growing demand
Mr Fouras said the contract reflected growing demand for 4DMedical’s innovative respiratory imaging solutions.
“Doing business with UCSD Health underscores a growing recognition of our innovative technology in transforming respiratory care,” he said.
“We believe its status as one of the best respiratory hospitals in the country will undoubtedly boost our commercialisation efforts within the broader US healthcare system.”
Find out more.
